These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 36969065)

  • 1. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
    Yuanren G; Yin L; Liu R; Cui Y
    Front Oncol; 2023; 13():1054072. PubMed ID: 36969065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
    Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
    Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
    Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
    Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
    Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
    Lin LW; Ke K; Yan LY; Chen R; Huang JY
    Front Oncol; 2023; 13():1178428. PubMed ID: 37207144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Zou X; Xu Q; You R; Yin G
    Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.
    Si T; Huang Z; Khorsandi SE; Ma Y; Heaton N
    Front Bioeng Biotechnol; 2022; 10():1010824. PubMed ID: 36237208
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
    Zhao S; Zhou M; Wang P; Yang J; Zhang D; Yin F; Song P
    Technol Cancer Res Treat; 2022; 21():15330338221133640. PubMed ID: 36259214
    [No Abstract]   [Full Text] [Related]  

  • 13. Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody followed by simultaneous transcatheter arterial chemoembolization, and portal vein embolization.
    Luo X; Chang RZ; Kuang D; Yuan M; Li GX; Zhang B; Wang YJ; Zhang WG; Ding ZY
    Front Immunol; 2023; 14():1285296. PubMed ID: 37928536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a meta-analysis.
    Zhao Q; Zhu K; Yue J; Qi Z; Jiang S; Xu X; Feng R; Wang R
    Ther Clin Risk Manag; 2017; 13():21-31. PubMed ID: 28053537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.
    Leung JH; Wang SY; Leung HWC; Chan ALF
    Front Oncol; 2024; 14():1344798. PubMed ID: 38434681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    An C; Fu Y; Li W; Zuo M; Wu P
    Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
    Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
    Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience.
    Zhao W; Liu C; Wu Y; Yao Z; Dou Q; Li W; Zhao X; Xia N
    Transl Cancer Res; 2024 May; 13(5):2315-2331. PubMed ID: 38881913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
    J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Li SQ; Wu JY; Wu JY; Xie H; Li JH; Zeng ZX; Fu YK; Liu DY; Li H; Chen WZ; Huang JY; Yan ML
    J Hepatocell Carcinoma; 2023; 10():1799-1811. PubMed ID: 37850080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.